Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2

Given the current impact of SARS-CoV2 and COVID-19 on human health and the global economy, the development of direct acting antivirals is of paramount importance. Main protease (M-Pro), a cysteine protease that cleaves the viral polyprotein, is essential for viral replication. Therefore, M-Pro is a novel therapeutic target. We identified two novel M-P(ro) inhibitors, D-FFRCMKyne and D-FFCitCMKyne, that covalently modify the active site cysteine (C14S) and determined cocrystal structures. Medicinal chemistry efforts led to SM141 and SM142, which adopt a unique binding mode within the M-P(ro) active site. Notably, these inhibitors do not inhibit the other cysteine protease, papain-like protease (PLPro), involved in the life cycle of SARS-CoV2. SM141 and SM142 block SARS-CoV2 replication in hACE2 expressing A549 cells with IC50, values of 8.2 and 14.7 nM. Detailed studies indicate that these compounds also inhibit cathepsin L (CatL), which cleaves the viral S protein to promote viral entry into host cells. Detailed biochemical, proteomic, and knockdown studies indicate that the antiviral activity of SM141 and SM142 results from the dual inhibition of M-P(ro) and CatL. Notably, intranasal and intraperitoneal administration of SM141 and SM142 lead to reduced viral replication, viral loads in the lung, and enhanced survival in SARS-CoV2 infected K18-ACE2 transgenic mice. In total, these data indicate that SM141 and SM142 represent promising scaffolds on which to develop antiviral drugs against SARS-CoV2.

Automated summary

The newly discovered M-Pro inhibitors SM141 and SM142 show promising potential as antiviral drugs against SARS-CoV2, effectively blocking viral replication. These inhibitors work by dual inhibition of M-Pro and CatL, reducing viral replication and improving survival rates in infected mice.